首页> 美国卫生研究院文献>other >The use of collagen matrix (Ologen) as a patch graft in glaucoma tube shunt surgery a retrospective chart review
【2h】

The use of collagen matrix (Ologen) as a patch graft in glaucoma tube shunt surgery a retrospective chart review

机译:回顾性图表回顾:胶原基质(Ologen)在青光眼分流手术中作为补片的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: To determine the safety and efficacy of collagen matrix as a patch graft in glaucoma drainage surgery. Collagen matrix grafts may be advantageous because they do not need to be harvested from human donors. >Methods: An institutional, retrospective review of 43 patients with at least 12 months follow-up status post-glaucoma drainage implant surgery were evaluated for signs of tube erosion after initial placement of collagen matrix patch graft. >Results: Forty-one of 43 eyes (95.3%) required no intervention for patch graft melting with tube erosion. Average time of follow-up was 32 months (range: 12-45). Two cases had tube erosion at 4 months and 26 months post-op requiring tube revision, which was successfully revised with conjunctiva (4 month erosion) and donor sclera (26 month erosion). >Conclusion:  Our results suggest that collagen matrix patch grafts may be used successfully as a patch graft in glaucoma tube shunt surgery, and may be advantageous because they do not have to be harvested from human donors. It is possible that exposure rates may be higher after longer follow-up and with larger numbers of patients. Further research is needed to compare Ologen to traditional graft materials to conclusively determine the safety and efficacy of collagen matrix as a novel patch graft material.
机译:>目的:确定青光眼引流手术中胶原基质作为贴片移植的安全性和有效性。胶原蛋白基质移植物可能是有利的,因为它们不需要从人类供体中收获。 >方法:对43例青光眼引流植入术后至少12个月随访状态的患者进行了系统的回顾性研究,评估了初次放置胶原基质膜片移植物后管侵蚀的迹象。 >结果:43只眼中有41只(95.3%)无需干预即可修补斑块状移植物并伴有管侵蚀。平均随访时间为32个月(范围:12-45)。 2例在术后4个月和26个月发生管糜烂,需要进行管翻修,并成功地通过结膜(4个月糜烂)和供体巩膜(26个月糜烂)进行了修复。 >结论:我们的结果表明,胶原基质贴片移植物可以成功地用作青光眼分流手术中的贴片移植物,并且可能是有利的,因为它们不必从人类供体中获取。更长的随访时间和更大的患者人数之后,暴露率可能更高。需要进一步研究以将Ologen与传统移植材料进行比较,以最终确定胶原基质作为新型贴片移植材料的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号